Noncoding RNAs As Novel Biomarkers in Pancreatic Cancer: What Do We Know?

Overview

Journal Future Oncol

Specialty Oncology

Date 2016 Nov 15

PMID 27841659

Citations 31

Authors

Maria C Previdi

Pietro Carotenuto

Domenico Zito

Rosantony Pandolfo

Chiara Braconi

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is an aggressive cancer of the digestive system, which is becoming a serious health problem worldwide. Overall survival for patients with pancreatic cancer is poor, mainly due to a lack of biomarkers to enable early diagnosis and a lack of prognostic markers that can inform decision-making, facilitating personalized treatment and an optimal clinical outcome. ncRNAs play an important role in pancreatic carcinogenesis. Here we review the literature on the role of ncRNAs as biomarkers in pancreatic cancer. We focus on the significance of ncRNAs as markers for early diagnosis, as prognostic biomarkers able to inform clinical management and as targets for novel therapeutics for patients with pancreatic cancer.

Citing Articles

Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.

Haller S, Essani K Biomedicines. 2024; 12(8).

PMID: 39200298 PMC: 11351728. DOI: 10.3390/biomedicines12081834.

A MiR181/Sirtuin1 regulatory circuit modulates drug response in biliary cancers.

Barbato A, Piscopo F, Salati M, Pollastro C, Evangelista L, Ferrante L Clin Exp Med. 2024; 24(1):74.

PMID: 38598008 PMC: 11006774. DOI: 10.1007/s10238-024-01332-0.

Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer.

Wei L, Sun J, Wang X, Huang Y, Huang L, Han L Front Cell Dev Biol. 2023; 11:1226639.

PMID: 37560164 PMC: 10407809. DOI: 10.3389/fcell.2023.1226639.

Cilia and Cancer: From Molecular Genetics to Therapeutic Strategies.

Carotenuto P, Gradilone S, Franco B Genes (Basel). 2023; 14(7).

PMID: 37510333 PMC: 10379587. DOI: 10.3390/genes14071428.

Identifying pancreatic cancer-associated miRNAs using weighted gene co-expression network analysis.

Lyu P, Hao Z, Zhang H, Li J Oncol Lett. 2022; 24(3):297.

PMID: 35949612 PMC: 9353221. DOI: 10.3892/ol.2022.13417.

References

Mittal A, Chitkara D, Behrman S, Mahato R . Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials. 2014; 35(25):7077-87. DOI: 10.1016/j.biomaterials.2014.04.053. View

Benz F, Roderburg C, Cardenas D, Vucur M, Gautheron J, Koch A . U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med. 2013; 45:e42. PMC: 3789266. DOI: 10.1038/emm.2013.81. View

Lahdaoui F, Delpu Y, Vincent A, Renaud F, Messager M, Duchene B . miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene. 2014; 34(6):780-8. DOI: 10.1038/onc.2014.11. View

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P . Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013; 21(5):986-94. PMC: 3666633. DOI: 10.1038/mt.2013.35. View

Arora S, Swaminathan S, Kirtane A, Srivastava S, Bhardwaj A, Singh S . Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine. 2014; 9:2933-42. PMC: 4069140. DOI: 10.2147/IJN.S61949. View

Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T . ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2015; 7(2):1608-18. PMC: 4811484. DOI: 10.18632/oncotarget.6450. View

Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W . Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Gastroenterology. 2014; 147(2):485-97.e18. DOI: 10.1053/j.gastro.2014.04.048. View

Quinn J, Chang H . Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2015; 17(1):47-62. DOI: 10.1038/nrg.2015.10. View

Morinaga S, Nakamura Y, Atsumi Y, Murakawa M, Yamaoku K, Aoyama T . Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy. Anticancer Res. 2016; 36(3):1083-8. View

10.

Johnson S, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A . RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. DOI: 10.1016/j.cell.2005.01.014. View

11.

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

12.

Gironella M, Seux M, Xie M, Cano C, Tomasini R, Gommeaux J . Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007; 104(41):16170-5. PMC: 2042180. DOI: 10.1073/pnas.0703942104. View

13.

Park J, Lee E, Esau C, Schmittgen T . Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009; 38(7):e190-9. DOI: 10.1097/MPA.0b013e3181ba82e1. View

14.

Peng W, Gao W, Feng J . Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014; 31(12):346. DOI: 10.1007/s12032-014-0346-4. View

15.

Frampton A, Gall T, Giovannetti E, Stebbing J, Castellano L, Jiao L . Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Rev Mol Diagn. 2013; 13(4):325-9. DOI: 10.1586/erm.13.18. View

16.

Clark M, Johnston R, Inostroza-Ponta M, Fox A, Fortini E, Moscato P . Genome-wide analysis of long noncoding RNA stability. Genome Res. 2012; 22(5):885-98. PMC: 3337434. DOI: 10.1101/gr.131037.111. View

17.

Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J . MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17):1901-8. DOI: 10.1001/jama.297.17.1901. View

18.

Xie Z, Yin X, Gong B, Nie W, Wu B, Zhang X . Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. Cancer Prev Res (Phila). 2014; 8(2):165-73. DOI: 10.1158/1940-6207.CAPR-14-0192. View

19.

Li J, Wu H, Li W, Yin L, Guo S, Xu X . Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene. 2016; 35(42):5501-5514. PMC: 5078861. DOI: 10.1038/onc.2016.90. View

20.

Giovannetti E, Funel N, Peters G, Del Chiaro M, Erozenci L, Vasile E . MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010; 70(11):4528-38. DOI: 10.1158/0008-5472.CAN-09-4467. View